Drugs Made In America Acquisition Corp.
DMAAUNasdaq
$10.99
↑ +2.5%Jul 16 close · end-of-day
Price
1Y↑ +5.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$6.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-90.2%
ROIC
—
Debt / Equity
—
Net Cash
$14,887.00
Return 1Y
+6.0%
Company profile
Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. Our executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 and our telephone number is (954) 870-3099.
- CEO
- Lynn Stockwell
- Sector
- Finance, Insurance, And Real Estate
- Industry
- Trading
- Employees
- 2
- Headquarters
- Florida
Earnings
DMAAU Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2025 |
|---|---|
| Revenue | — |
| Gross profit | — |
| Operating income | -$2.8M |
| Net income | $5.9M |
| Diluted EPS | — |
| Operating cash flow | -$539,187.00 |
| Free cash flow | — |
| Gross margin | — |
| Operating margin | — |
| Net margin | — |
| Line item | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$144,928.00 | -$330,925.00 | -$131,919.00 | -$263,703.00 | -$2.1M | -$143,301.00 |
| Net income | -$144,928.00 | $1.3M | $2.3M | $2.2M | $212,958.00 | $2.0M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | — | -$251,244.00 | -$106,655.00 | -$56,108.00 | -$125,180.00 | -$91,250.00 |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
Company news
Feb 24, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.